Core Viewpoint - The company, Aihuilong (688575.SH), has received a medical device registration certificate from the National Medical Products Administration for its product, which is a kit for the quantitative determination of human chorionic gonadotropin and its beta subunit in human serum and/or plasma [1] Group 1 - The product is primarily used for dynamic monitoring of malignant tumor patients to assist in assessing disease progression or treatment effectiveness [1] - The kit is not intended for early diagnosis or confirmation of malignant tumors and is not used for tumor screening in the general population [1]

Group 1 - Company MengTian Home is planning to acquire control of ChuanTu Microelectronics through a combination of issuing shares and cash payment, which is expected to constitute a major asset restructuring [1] - The actual controller of MengTian Home, Yu Jingyuan, is also planning a transfer of control, which is independent of the aforementioned acquisition [1] - The stock of MengTian Home has been suspended since November 6, 2025, with an expected suspension period of no more than 10 trading days [1] Group 2 - Kweichow Moutai plans to repurchase shares with an investment of between 1.5 billion and 3 billion RMB, with a maximum repurchase price of 1,887.63 RMB per share [2] - The repurchase will be conducted through centralized bidding and will be used for cancellation to reduce the company's registered capital [2] - The company also plans to distribute a cash dividend of 23.957 RMB per share, totaling approximately 30 billion RMB based on the total share capital as of September 30, 2025 [2] Group 3 - JiaYuan Technology has signed a cooperation framework agreement with CATL to deepen their long-term procurement cooperation in the supply, research, and production of materials for new battery anodes [3] - The agreement aims to enhance collaboration in technology research and market expansion, benefiting both companies [3] - JiaYuan Technology will be the preferred supplier for new products developed in cooperation with CATL, which will strengthen its competitive position in the industry [3] Group 4 - KaBeiYi has invested 100 million RMB to establish a wholly-owned subsidiary, Shanghai KaBeiYi Robotics, to accelerate the development of humanoid robot components [4] - The new subsidiary will operate independently and is expected to enhance the company's investment in humanoid robotics [4] Group 5 - Bertley has established a joint venture, Wuhu Bertley Drive Technology Co., Ltd., with a registered capital of 100 million RMB, where Bertley holds a 60% stake [5] - The joint venture will focus on the research, production, and sales of various electric motors, aligning with the company's strategy for technological autonomy and product diversification [5] - This strategic move is aimed at strengthening the company's position in high-growth sectors such as new energy vehicles and humanoid robotics [5] Group 6 - Tongling Nonferrous Metals has successfully acquired exploration rights for the JiGuangShan-HuVillage copper-gold-molybdenum mine for 3.204 billion RMB [6] - Ningbo Port expects to achieve a container throughput of 4.56 million TEUs in October 2025, representing a year-on-year increase of 12.4% [6] - Hongquan Technology will change its stock name to Hongquan Technology starting November 11, 2025, while maintaining its full name and stock code [6] Group 7 - Dongfeng Group has undergone a change in its controlling shareholder and actual controller, leading to a name change to Quzhou Dongfeng New Materials Group Co., Ltd. [7] - Yihong Long has been recognized as a national manufacturing single champion enterprise for its self-immune disease diagnostic products [7] Group 8 - China Shipbuilding Technology's subsidiary plans to publicly transfer 100% equity of a clean energy development company as part of its strategy to enhance operational quality and fund future projects [8] - HeimuDan's subsidiary is selling its developed digital economy industrial park properties for approximately 41.97 million RMB [8] Group 9 - Shenkai Co. has completed the transfer of shares from its original controlling shareholder to Shenzhen Huili Hongsheng Industrial Holdings, changing its controlling shareholder [9] - Luzhou Laojiao is investing approximately 1.478 billion RMB to build a historical and cultural industry park to enhance brand influence [9] Group 10 - Xiling Power has signed a share purchase agreement to acquire 100% of Weipai Automotive Electronics, which specializes in turbocharger production [10] - Mind Electronics plans to divest its 51% stake in a subsidiary for 14.8 million RMB to focus on core business development [10] Group 11 - Triangle Defense has signed development and framework order agreements with Siemens Energy to supply specific items, enhancing its international market presence [11] Group 12 - Hualan Co.'s controlling shareholder plans to increase its stake in the company by investing between 30 million and 60 million RMB [12] - Key executives of Kaili Medical have also increased their stakes in the company through market transactions [12]

Group 1 - Mengtian Home intends to acquire control of ChuanTu Microelectronics through a combination of share issuance and cash payment, leading to a significant asset restructuring. The stock will be suspended from trading starting November 6, 2025, for up to 10 trading days [2] - Guizhou Moutai plans to repurchase shares worth between 1.5 billion and 3 billion RMB, with a maximum repurchase price of 1,887.63 RMB per share. The repurchase will be completed within six months following shareholder approval [3] - Jiayuan Technology has signed a cooperation framework agreement with CATL to deepen their long-term procurement relationship, focusing on the supply and development of materials for new battery anodes [4] Group 2 - Kabeiyi has invested 100 million RMB to establish a wholly-owned subsidiary, Shanghai Kabeiyi Robotics, to accelerate the development of humanoid robot components [5] - Bertley has formed a joint venture with Langfang Jinrun Electric to establish Wuhu Bertley Drive Technology Co., with a registered capital of 100 million RMB, focusing on electric motor systems [7] - Tongling Nonferrous Metals has successfully acquired exploration rights for the Jiguanshan-Hucun copper-gold-molybdenum mine for 3.204 billion RMB [8] Group 3 - Ningbo Port expects to achieve a container throughput of 4.56 million TEUs in October 2025, representing a year-on-year increase of 12.4% [8] - Huayuan Technology has changed its stock name from "Hongquan Technology" to "Hongquan Technology" effective November 11, 2025, while maintaining its full name and stock code [8] - The company plans to invest approximately 1.478 billion RMB in the construction of a historical and cultural industry park to enhance brand influence [12]

Core Points - Company Aihuilong has been recognized as a national-level manufacturing champion enterprise in the ninth batch announced by the Shenzhen Municipal Bureau of Industry and Information Technology [2] - The product that contributed to this recognition is the company's self-immune disease diagnostic products [2]

特此公告。 深圳市亚辉龙生物科技股份有限公司董事会 2025 年 11 月 6 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据深圳市工业和信息化局近日发布的《关于第九批制造业单项冠军企业和复核通 过第三批、第六批制造业单项冠军企业名单的公示》，深圳市亚辉龙生物科技股份有限 公司（以下简称"公司"或"亚辉龙"）成功入选第九批国家级制造业单项冠军企业， 入选产品为公司的"自身免疫疾病诊断产品"。 制造业单项冠军企业是指长期专注于制造业特定细分领域，生产技术或工艺水平国 际先进，单项产品（生产性服务）市场占有率位居全球或国内前列的企业。单项冠军企 业是制造业创新发展的领头雁、排头兵，代表全球制造业细分领域最高发展水平、最强 市场实力，是制造业竞争力的重要体现。 亚辉龙秉承"专注生命健康事业，努力让科技造福人类"的使命，专注于体外诊断 领域的研发与创新，始终如一、追求卓越，不断为人类生命健康事业提供卓越的产品及 服务。经过十余年的耕耘，公司已成长为国产化学发光领导品牌之一，在自身免疫、生 殖健康、糖尿病、感染性疾病、肝病 ...

Core Viewpoint - The company has been recognized as a national-level manufacturing champion enterprise for its autoimmune disease diagnostic products, which enhances its brand influence and market competitiveness, although it will not significantly impact current performance [1] Group 1 - The company has been selected for the ninth batch of national-level manufacturing champion enterprises by the Shenzhen Municipal Bureau of Industry and Information Technology [1] - The recognized product is the "autoimmune disease diagnostic products," indicating a strong technological and quality standard [1] - This recognition reflects the company's overall strength and is expected to positively influence its operations [1]

Core Points - Company Aihuilong (688575.SH) has been recognized as a national-level manufacturing single champion enterprise in the ninth batch by the Shenzhen Municipal Bureau of Industry and Information Technology [1] - The product that earned this recognition is the company's autoimmune disease diagnostic products [1] Summary by Category Company Recognition - Aihuilong has successfully entered the list of national-level manufacturing single champion enterprises [1] - This recognition highlights the company's strength in the manufacturing sector, particularly in the field of diagnostic products [1] Product Focus - The specific product recognized is the autoimmune disease diagnostic product, indicating the company's focus on healthcare and diagnostics [1] - This achievement may enhance the company's reputation and market position within the healthcare industry [1]

Core Viewpoint - Company Aihuilong (688575.SH) has been recognized as a national-level manufacturing single champion enterprise, specifically for its autoimmune disease diagnostic products, which reflects the company's technological and quality excellence [1][1][1] Group 1 - The recognition as a national-level manufacturing single champion enterprise is a validation of the company's product technology and quality [1] - This achievement highlights the company's industry position and independent innovation capabilities [1] - The recognition is expected to enhance the brand influence and market competitiveness of the company's products, leading to positive operational impacts [1]

Core Viewpoint - Company Aihuilong (688575.SH) has been recognized as a national-level manufacturing champion enterprise, specifically for its autoimmune disease diagnostic products, which reflects the company's technological and quality excellence [1] Group 1: Recognition and Impact - The inclusion in the ninth batch of national-level manufacturing champion enterprises is a recognition of the company's product technology and quality [1] - This recognition enhances the company's industry position and demonstrates its independent innovation capabilities [1] - The acknowledgment is expected to strengthen the brand influence and market competitiveness of the company's products, leading to positive operational impacts [1]

Core Viewpoint - The company reported a decline in overall revenue and net profit for the first three quarters of 2025, but showed signs of recovery in Q3, particularly in domestic operations and overseas growth [1][2]. Group 1: Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 1.287 billion yuan, a year-on-year decrease of 7.69%, and a net profit attributable to shareholders of 60 million yuan, down 72.36% year-on-year [1]. - In Q3 2025, the company recorded a revenue of 478 million yuan, representing a year-on-year increase of 10.25%, while the net profit attributable to shareholders was 34 million yuan, down 25.12% year-on-year [1]. Group 2: Domestic and Overseas Performance - Domestic revenue for the main business was 1.074 billion yuan, a year-on-year decrease of 5.9%, while overseas business saw a significant growth with a revenue of 208 million yuan, up 39% year-on-year [2]. - In Q3 2025, domestic main business revenue reached 403 million yuan, a year-on-year increase of 14.4%, with overseas revenue growing by 68.5% year-on-year [2]. Group 3: Equipment Installation and Market Expansion - The company installed 1,806 new light-emitting devices in the first three quarters of 2025, with a total installation exceeding 12,410 units [3]. - The company’s unique pipeline products have gained recognition, with a specific diagnostic reagent entering the industrialization phase [3]. Group 4: Profit Forecast - The company forecasts total revenues of 1.885 billion yuan, 2.173 billion yuan, and 2.546 billion yuan for 2025-2027, with respective year-on-year growth rates of -6.29%, 15.29%, and 17.17% [4]. - The projected net profit attributable to shareholders for the same period is 119 million yuan, 291 million yuan, and 407 million yuan, with year-on-year growth rates of -60.61%, 144.63%, and 40.19% [4].